Back

Heparin reversal for coronary artery perforation

31 August 2024 (11:00 - 11:50)
Organised by: Logo
Congress Presentation Part of: Complex or complicated? challenges of percutaneous coronary interventions Complications ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Yuichi Sawayama

Kurashiki Central Hospital, Kurashiki (Japan)

7 More presentations in this session

Presentation thumbnail
Retrograde coronary chronic total occlusion intervention (JR-CTO) score: from the Japanese CTO-PCI expert registry
Doctor H. Tanaka (Kurashiki, JP)
Abstract Slides Video
Presentation thumbnail
Insights into retroperitoneal hemorrhage management: result from a tertiary cardiovascular center prospective cohort
Associate Professor P. Sadeghipour (Tehran, IR)
Abstract Slides Video
Presentation thumbnail
Association between in-hospital haemoglobin drop with or without overt bleeding and long-term clinical outcomes after percutaneous coronary intervention
Doctor T. Suzuki (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Association between J-scores and ostial lesions: quantifying the effects of ostial lesions in chronic total occlusion percutaneous interventions
Mr B. Salloum (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
The acute procedural results and subsequent clinical outcomes after CTO-PCI: main-analysis of the japanese CTO-PCI expert registry
Doctor H. Matsuda (Nagoya, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Complex or complicated? challenges of percutaneous coronary interventions

The Event

Event poster

ESC Congress 2024

31 August 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes of comparison between type-III cap and non-cap acute coronary syndrome patients in 3 year follow up
thumbnail
Congress Session
Acute coronary syndromes and high-risk PCI: state of the art
thumbnail
Congress Presentation
Post-PCI anticoagulation with unfractionated heparin in acute coronary syndrome: insight from the STOPDAPT-3 trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources